You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 131 No. 6, June 1995 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Observations
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Leukocytoclastic Vasculitis Following Staphylococcal Protein A Column Immunoadsorption Therapy

Two Cases and a Review of the Literature

Jack L. Arbiser, MD; Jeffery S. Dzieczkowski, MD; James V. Harmon, MD; Lyn M. Duncan, MD

Arch Dermatol. 1995;131(6):707-709.


Abstract



Background
Protein A immunoadsorption is a novel therapy for the treatment of diseases mediated by pathogenic autoantibodies. This procedure consists of circulating patients' plasma through a column containing staphylococcal protein A, which binds to the Fc portion of IgG, enabling removal of IgG. Presently, protein A immunoadsorption is used in the treatment of idiopathic thrombocytopenic purpura, but may be more widely used as an immunomodulator in human immunodeficiency virus infection and metastatic carcinoma.

Observations
We present two histologically documented cases of leukocytoclastic vasculitis in the setting of protein A immunoadsorption. This potentially severe adverse effect is probably more common than the literature reflects and should be recognized by physicians who are treating patients with protein A column pheresis.

Conclusions
The pathogenesis of protein A therapy-associated leukocytoclastic vasculitis remains unclear. Further study of vasculitis in the setting of protein A column pheresis may lead to modifications of this therapy, resulting in fewer adverse effects. Protein A-associated leukocytoclastic vasculitis may serve as a useful model of the relation of immune complexes and vasculitis.

(Arch Dermatol. 1995;131:707-709)



Author Affiliations



From the Departments of Dermatology (Dr Arbiser) and Pathology (Dr Duncan), Massachusetts General Hospital and Harvard Medical School, Boston; the Department of Pathology, Wayne State University, Detroit, Mich (Dr Dzieczkowski; and the Department of Surgery, University of Minnesota, Minneapolis (Dr Harmon).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pathogenesis of B-Cell Superantigen-Induced Immune Complex-Mediated Inflammation
Anderson et al.
Infect. Immun. 2006;74:1196-1203.
ABSTRACT | FULL TEXT  

In Vivo Inflammatory Response to a Prototypic B Cell Superantigen: Elicitation of an Arthus Reaction by Staphylococcal Protein A
Kozlowski et al.
J. Immunol. 1998;160:5246-5252.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.